Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of...
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...
Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical...
Josep Bassaganya-Riera Steps Down as Chairman, President and CEO Tim M. Mayleben Appointed Interim President and CEO Chris Garabedian Appointed...
Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND...
Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma,...
BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its...
BLACKSBURG, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE ® advanced A.I. platform to develop novel...
Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021
Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling